Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation.

Darren Wong, William Thomas, Andrew Butler, Lisa Sharkey

BMJ case reports 2021 May 12

filter terms:

A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Citation

Darren Wong, William Thomas, Andrew Butler, Lisa Sharkey. Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation. BMJ case reports. 2021 May 12;14(5)